Immunotherapy in colorectal cancer: rationale, challenges and potential

Karuna Ganesh(Memorial Sloan Kettering Cancer Center), Zsofia K. Stadler(Memorial Sloan Kettering Cancer Center), Andrea Cercek(Memorial Sloan Kettering Cancer Center), Robin B. Mendelsohn(Memorial Sloan Kettering Cancer Center), Jinru Shia(Memorial Sloan Kettering Cancer Center), Neil H. Segal(Memorial Sloan Kettering Cancer Center), Luis A. Díaz(Memorial Sloan Kettering Cancer Center)
Nature Reviews Gastroenterology & Hepatology
March 18, 2019
10.1038/s41575-019-0126-x
Cited by 2,002Open Access
Full Text

Abstract

Related Papers

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al.|New England Journal of Medicine|2015|9.4k
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al.|New England Journal of Medicine|2015|6.2k
The consensus molecular subtypes of colorectal cancer
Justin Guinney, Rodrigo Dienstmann, Xin Wang et al.|Nature Medicine|2015|5.2k
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Gabriela Bindea, Bernhard Mlecnik, Marie Tosolini et al.|Immunity|2013|4.7k
Tumour-educated macrophages promote tumour progression and metastasis
Jeffrey W. Pollard|Nature reviews. Cancer|2004|3.4k